Eli Lilly & Co. (LLY) Announces Significant Data from Trulicity Combo Phase 3 in T2D Glycemic Control
Tweet Send to a Friend
New data from a completed Phase 3 trial show Trulicity (dulaglutide) 1.5 mg significantly reduced hemoglobin A1c (A1C) and body ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
